ArticleFrontiers in immunology2026
Epithelial CXCL1 tracks clinical remission in inflammatory bowel disease in a disease-specific manner.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory and Immune Cytoprofiles of Active Ulcerative Colitis from Crohn's Disease-Insights from Multivariable Modeling.International journal of molecular sciences · 2026Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Introduction: Stem cell-derived organoids are promising platforms for therapeutic screening in inflammatory bowel disease (IBD), but identifying functional organoid readouts with translational utility is challenging. Colon epithelial organoids from patients with ulcerative colitis (UC) overexpress chemokines CXCL1, CXCL11, CCL2, and CCL28, yet whether these epithelial inflammatory signatures correlate with disease activity and treatment response is unclear. This brief report explores whether organoid-retained chemokines correlate with disease activity and therapeutic outcomes. Methods: We interrogated three bulk and two single-cell transcriptomic datasets from IBD clinical trials encompassing anti-TNFα and anti-integrin therapies to determine whether epithelial chemokines retained in UC organoids are associated with clinical response and distinguish treatment responders from non-responders to biologic therapy across multiple IBD patient cohorts. Results: In bulk transcriptomic data, CXCL1, CXCL11, and CCL2 were elevated in active UC and normalized only in patients achieving clinical remission, independent of therapy class, with persistent chemokine overexpression in non-responders. Linear regression analysis demonstrated that CXCL1 showed the strongest and most consistent association with Mayo clinical disease activity scores across independent cohorts. Single-cell analysis of epithelial cell types identified CXCL1 as the only chemokine significantly enriched in both enterocytes and LGR5-positive stem cells in UC. CXCL1 expression normalized in remission but remained elevated in non-remission patients, and this pattern was recapitulated in LGR5-high stem cell states. Epithelial CXCL1 expression was not associated with clinical remission in Crohn's disease. Conclusions: CXCL1 is a remission-associated epithelial chemokine in UC and may represent a candidate biomarker and functional endpoint for epithelial-directed therapeutic screening using patient-derived organoid models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.